NeoImmune

China
Shimenjie, Jiangxi, China, 518000

Company profile

NeoImmune company profile

Universal Medicine is a technology developer in the field of immune system, dedicated to the development of key technologies for high-throughput reading and writing of T and B lymphocyte receptor profiles and their applications in clinical testing and treatment, focusing on technology developers in the field of immune system . Recently announced the completion of a 30 million RMB Pre-A round of strategic financing. WinX Capital is acting as a financial advisor. This round of investment was initiated by Kangsheng Global. Ruijiang Kangsheng Fund managed by Ruijiang Investment led the investment. The investors included Spark Venture Capital and Yangtze River Source Fund. This round of funds will be mainly used for the promotion of hematological tumor MRD products and the research and development of new clinical products.

Business identity

Contact email
[email protected]
Phone number
+86 0755-32960061
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2019-12-01, Month

Headquarters

Postal code
518000
Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$4.7M
Last funding
Seed / $4.7M / 2021-11-25
Last equity funding
Seed / $4.7M
Investors
5
Lead investors
2

Founders and investors

Lead investors

Kindstar Global (Beijing) Medicine TechnologyWinX Capital

Investors

Changjiang FundKindstar Global (Beijing) Medicine TechnologyRuijing InvestmentSpark VenturesWinX Capital